Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies
Objective: To study the usefulness of maternal serum insulin-like growth factor binding protein-3, a potential cell growth inhibitor, in second trimester prenatal screening for fetal Down syndrome. Methods: Three hundred and forty-two samples from normal pregnancies and nine fetal Down syndrome preg...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 1998-02, Vol.91 (2), p.192-195 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 2 |
| container_start_page | 192 |
| container_title | Obstetrics and gynecology (New York. 1953) |
| container_volume | 91 |
| creator | Chu, D.C Hsu, C Wenstrom, K.D Boots, L.R |
| description | Objective: To study the usefulness of maternal serum insulin-like growth factor binding protein-3, a potential cell growth inhibitor, in second trimester prenatal screening for fetal Down syndrome.
Methods: Three hundred and forty-two samples from normal pregnancies and nine fetal Down syndrome pregnancies were analyzed for insulin-like growth factor binding protein-3 levels by radioimmunoassay. Data were converted to multiples of median (MoM) and analyzed statistically to compare the differences between control and Down syndrome pregnancies.
Results: The mean insulin-like growth factor binding protein-3 MoM of Down syndrome–affected pregnancies (1.09) was significantly higher than that of the normal pregnancies (1.00) (
P < .01). Insulin-like growth factor binding protein-3, in combination with maternal serum alpha-fetoprotein (MSAFP), hCG, and maternal age, detected 89% of Down syndrome pregnancies at a screen positive rate of 2.1%. This compares favorably to the standard combination of MSAFP, hCG, and unconjugated estriol (E3), which had a 66.7% Down syndrome detection rate and a 4.1% screen positive rate in our study samples.
Conclusion: This retrospective analysis suggested that the inclusion of insulin-like growth factor binding protein-3 into the triple screen program to replace unconjugated E3 might enhance the detection rate of fetal Down syndrome pregnancies. These data need to be confirmed by a larger prospective study. |
| doi_str_mv | 10.1016/S0029-7844(97)00662-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79684261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0029784497006625</els_id><sourcerecordid>79684261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4347-283cbc4613f0eba6336ae537d664fc9ca32134534c8d429ca8c13a9b834130f03</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxS1EVULgI1TyASE4LPW_9a5PqLSkVKpUpILEzTje2cbUsYvtJeq3x2miXHuyxvPePPs3CJ1Q8okSKk9vCWGq6XohPqjuIyFSsqZ9gWa073jDOP_1Es0Oklfodc5_CKlGxY_RsRJSsU7M0O-rkCfvQuPdPeDLFDdlhRfGlpjwFxcGF-7w9xQLVAnHLuCyAnwBBWxxMeA44gUU4_FF3AR8-xiGFNdQHXAXTLAO8ht0NBqf4e3-nKOfi68_zr811zeXV-dn140VXHQN67ldWiEpHwksjeRcGmh5N0gpRqus4Yxy0XJh-0GwWveWcqOWPReUk5HwOXq_m_uQ4t8JctFrly14bwLEKetOyV6wOn-O2p3QpphzglE_JLc26VFTordk9RNZvcWmVaefyOq2-k72AdNyDcPBtUdZ--_2fZOt8WPa_j8fZIyKuhRZZWIn20RfIOV7P20g6RUYX1Y1rMaxljRUqZ6wWjXbq67aPu9sUBn-c9WRK91gYXCp7kIP0T3z_v82o6Om</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79684261</pqid></control><display><type>article</type><title>Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Chu, D.C ; Hsu, C ; Wenstrom, K.D ; Boots, L.R</creator><creatorcontrib>Chu, D.C ; Hsu, C ; Wenstrom, K.D ; Boots, L.R</creatorcontrib><description>Objective: To study the usefulness of maternal serum insulin-like growth factor binding protein-3, a potential cell growth inhibitor, in second trimester prenatal screening for fetal Down syndrome.
Methods: Three hundred and forty-two samples from normal pregnancies and nine fetal Down syndrome pregnancies were analyzed for insulin-like growth factor binding protein-3 levels by radioimmunoassay. Data were converted to multiples of median (MoM) and analyzed statistically to compare the differences between control and Down syndrome pregnancies.
Results: The mean insulin-like growth factor binding protein-3 MoM of Down syndrome–affected pregnancies (1.09) was significantly higher than that of the normal pregnancies (1.00) (
P < .01). Insulin-like growth factor binding protein-3, in combination with maternal serum alpha-fetoprotein (MSAFP), hCG, and maternal age, detected 89% of Down syndrome pregnancies at a screen positive rate of 2.1%. This compares favorably to the standard combination of MSAFP, hCG, and unconjugated estriol (E3), which had a 66.7% Down syndrome detection rate and a 4.1% screen positive rate in our study samples.
Conclusion: This retrospective analysis suggested that the inclusion of insulin-like growth factor binding protein-3 into the triple screen program to replace unconjugated E3 might enhance the detection rate of fetal Down syndrome pregnancies. These data need to be confirmed by a larger prospective study.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1016/S0029-7844(97)00662-5</identifier><identifier>PMID: 9469274</identifier><identifier>CODEN: OBGNAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; alpha-Fetoproteins - analysis ; Biological and medical sciences ; Biomarkers - blood ; Chorionic Gonadotropin - blood ; Down Syndrome - diagnosis ; Estriol - blood ; Female ; Fetal Diseases - diagnosis ; Gynecology. Andrology. Obstetrics ; Humans ; Infant, Newborn ; Insulin-Like Growth Factor Binding Protein 3 - blood ; Logistic Models ; Management. Prenatal diagnosis ; Medical sciences ; Pregnancy ; Pregnancy Trimester, Second ; Pregnancy. Fetus. Placenta ; Prenatal Diagnosis ; Radioimmunoassay ; Retrospective Studies</subject><ispartof>Obstetrics and gynecology (New York. 1953), 1998-02, Vol.91 (2), p.192-195</ispartof><rights>1998 The American College of Obstetricians and Gynecologists</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4347-283cbc4613f0eba6336ae537d664fc9ca32134534c8d429ca8c13a9b834130f03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2142336$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9469274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, D.C</creatorcontrib><creatorcontrib>Hsu, C</creatorcontrib><creatorcontrib>Wenstrom, K.D</creatorcontrib><creatorcontrib>Boots, L.R</creatorcontrib><title>Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Objective: To study the usefulness of maternal serum insulin-like growth factor binding protein-3, a potential cell growth inhibitor, in second trimester prenatal screening for fetal Down syndrome.
Methods: Three hundred and forty-two samples from normal pregnancies and nine fetal Down syndrome pregnancies were analyzed for insulin-like growth factor binding protein-3 levels by radioimmunoassay. Data were converted to multiples of median (MoM) and analyzed statistically to compare the differences between control and Down syndrome pregnancies.
Results: The mean insulin-like growth factor binding protein-3 MoM of Down syndrome–affected pregnancies (1.09) was significantly higher than that of the normal pregnancies (1.00) (
P < .01). Insulin-like growth factor binding protein-3, in combination with maternal serum alpha-fetoprotein (MSAFP), hCG, and maternal age, detected 89% of Down syndrome pregnancies at a screen positive rate of 2.1%. This compares favorably to the standard combination of MSAFP, hCG, and unconjugated estriol (E3), which had a 66.7% Down syndrome detection rate and a 4.1% screen positive rate in our study samples.
Conclusion: This retrospective analysis suggested that the inclusion of insulin-like growth factor binding protein-3 into the triple screen program to replace unconjugated E3 might enhance the detection rate of fetal Down syndrome pregnancies. These data need to be confirmed by a larger prospective study.</description><subject>Adult</subject><subject>alpha-Fetoproteins - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Chorionic Gonadotropin - blood</subject><subject>Down Syndrome - diagnosis</subject><subject>Estriol - blood</subject><subject>Female</subject><subject>Fetal Diseases - diagnosis</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Insulin-Like Growth Factor Binding Protein 3 - blood</subject><subject>Logistic Models</subject><subject>Management. Prenatal diagnosis</subject><subject>Medical sciences</subject><subject>Pregnancy</subject><subject>Pregnancy Trimester, Second</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>Prenatal Diagnosis</subject><subject>Radioimmunoassay</subject><subject>Retrospective Studies</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9vEzEQxS1EVULgI1TyASE4LPW_9a5PqLSkVKpUpILEzTje2cbUsYvtJeq3x2miXHuyxvPePPs3CJ1Q8okSKk9vCWGq6XohPqjuIyFSsqZ9gWa073jDOP_1Es0Oklfodc5_CKlGxY_RsRJSsU7M0O-rkCfvQuPdPeDLFDdlhRfGlpjwFxcGF-7w9xQLVAnHLuCyAnwBBWxxMeA44gUU4_FF3AR8-xiGFNdQHXAXTLAO8ht0NBqf4e3-nKOfi68_zr811zeXV-dn140VXHQN67ldWiEpHwksjeRcGmh5N0gpRqus4Yxy0XJh-0GwWveWcqOWPReUk5HwOXq_m_uQ4t8JctFrly14bwLEKetOyV6wOn-O2p3QpphzglE_JLc26VFTordk9RNZvcWmVaefyOq2-k72AdNyDcPBtUdZ--_2fZOt8WPa_j8fZIyKuhRZZWIn20RfIOV7P20g6RUYX1Y1rMaxljRUqZ6wWjXbq67aPu9sUBn-c9WRK91gYXCp7kIP0T3z_v82o6Om</recordid><startdate>199802</startdate><enddate>199802</enddate><creator>Chu, D.C</creator><creator>Hsu, C</creator><creator>Wenstrom, K.D</creator><creator>Boots, L.R</creator><general>Elsevier Inc</general><general>The American College of Obstetricians and Gynecologists</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199802</creationdate><title>Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies</title><author>Chu, D.C ; Hsu, C ; Wenstrom, K.D ; Boots, L.R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4347-283cbc4613f0eba6336ae537d664fc9ca32134534c8d429ca8c13a9b834130f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>alpha-Fetoproteins - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Chorionic Gonadotropin - blood</topic><topic>Down Syndrome - diagnosis</topic><topic>Estriol - blood</topic><topic>Female</topic><topic>Fetal Diseases - diagnosis</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Insulin-Like Growth Factor Binding Protein 3 - blood</topic><topic>Logistic Models</topic><topic>Management. Prenatal diagnosis</topic><topic>Medical sciences</topic><topic>Pregnancy</topic><topic>Pregnancy Trimester, Second</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>Prenatal Diagnosis</topic><topic>Radioimmunoassay</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, D.C</creatorcontrib><creatorcontrib>Hsu, C</creatorcontrib><creatorcontrib>Wenstrom, K.D</creatorcontrib><creatorcontrib>Boots, L.R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, D.C</au><au>Hsu, C</au><au>Wenstrom, K.D</au><au>Boots, L.R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>1998-02</date><risdate>1998</risdate><volume>91</volume><issue>2</issue><spage>192</spage><epage>195</epage><pages>192-195</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><coden>OBGNAS</coden><abstract>Objective: To study the usefulness of maternal serum insulin-like growth factor binding protein-3, a potential cell growth inhibitor, in second trimester prenatal screening for fetal Down syndrome.
Methods: Three hundred and forty-two samples from normal pregnancies and nine fetal Down syndrome pregnancies were analyzed for insulin-like growth factor binding protein-3 levels by radioimmunoassay. Data were converted to multiples of median (MoM) and analyzed statistically to compare the differences between control and Down syndrome pregnancies.
Results: The mean insulin-like growth factor binding protein-3 MoM of Down syndrome–affected pregnancies (1.09) was significantly higher than that of the normal pregnancies (1.00) (
P < .01). Insulin-like growth factor binding protein-3, in combination with maternal serum alpha-fetoprotein (MSAFP), hCG, and maternal age, detected 89% of Down syndrome pregnancies at a screen positive rate of 2.1%. This compares favorably to the standard combination of MSAFP, hCG, and unconjugated estriol (E3), which had a 66.7% Down syndrome detection rate and a 4.1% screen positive rate in our study samples.
Conclusion: This retrospective analysis suggested that the inclusion of insulin-like growth factor binding protein-3 into the triple screen program to replace unconjugated E3 might enhance the detection rate of fetal Down syndrome pregnancies. These data need to be confirmed by a larger prospective study.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9469274</pmid><doi>10.1016/S0029-7844(97)00662-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0029-7844 |
| ispartof | Obstetrics and gynecology (New York. 1953), 1998-02, Vol.91 (2), p.192-195 |
| issn | 0029-7844 1873-233X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79684261 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Adult alpha-Fetoproteins - analysis Biological and medical sciences Biomarkers - blood Chorionic Gonadotropin - blood Down Syndrome - diagnosis Estriol - blood Female Fetal Diseases - diagnosis Gynecology. Andrology. Obstetrics Humans Infant, Newborn Insulin-Like Growth Factor Binding Protein 3 - blood Logistic Models Management. Prenatal diagnosis Medical sciences Pregnancy Pregnancy Trimester, Second Pregnancy. Fetus. Placenta Prenatal Diagnosis Radioimmunoassay Retrospective Studies |
| title | Insulin-like Growth Factor Binding Protein-3 in the Detection of Fetal Down Syndrome Pregnancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A51%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin-like%20Growth%20Factor%20Binding%20Protein-3%20in%20the%20Detection%20of%20Fetal%20Down%20Syndrome%20Pregnancies&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=Chu,%20D.C&rft.date=1998-02&rft.volume=91&rft.issue=2&rft.spage=192&rft.epage=195&rft.pages=192-195&rft.issn=0029-7844&rft.eissn=1873-233X&rft.coden=OBGNAS&rft_id=info:doi/10.1016/S0029-7844(97)00662-5&rft_dat=%3Cproquest_cross%3E79684261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79684261&rft_id=info:pmid/9469274&rft_els_id=S0029784497006625&rfr_iscdi=true |